High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 To prevent pathogen recognition receptor and antiviral-gene expression

Journal of Virology

Volumn 85, Issue 21, 2011, Pages 11372-11380

  Reiser, Jeanette ^a   Hurst, José ^a   Voges, Maike ^a   Krauss, Peter ^a   Münch, Peter ^a   Iftner, Thomas ^a   Stubenrauch, Frank ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; DNA METHYLTRANSFERASE INHIBITOR; INTERFERON; INTERFERON LAMBDA 2; INTERFERON LAMBDA 3; INTERLEUKIN 29; KAPPA INTERFERON; PATHOGEN RECOGNITION RECEPTOR; PDZ PROTEIN; PROTEIN E6; PROTEIN MDA5; RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; E6 ONCOGENE; E7 ONCOGENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; IFIT1 GENE; KERATINOCYTE; MX1 GENE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; STAT1 GENE; TRAIL GENE; VIRUS GENE; VIRUS GENOME; XAF1 GENE;

CELL LINE; DOWN-REGULATION; GENE EXPRESSION; HUMANS; IMMUNE EVASION; INTERFERON TYPE I; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; TRANSCRIPTION, GENETIC;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 80055107582     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05279-11     Document Type: Article

References (45)

1. Ablasser, A., et al. 2009. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat. Immunol. 10:1065-1072.
2. Antonsson, A., E. Payne, K. Hengst, and N. A. McMillan. 2006. The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation. J. Interferon Cytokine Res. 26:455-461.
3. Bedell, M. A., et al. 1991. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J. Virol. 65:2254-2260.
4. Bodily, J. M., K. P. Mehta, and L. A. Laimins. 2011. Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer Res. 71:1187-1195.
5. Borden, E. C., et al. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6:975-990.
6. Bowie, A. G., and L. Unterholzner. 2008. Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immunol. 8:911-922.
7. Buontempo, P. J., et al. 2006. Antiviral activity of transiently expressed IFN-kappa is cell-associated. J. Interferon Cytokine Res. 26:40-52.
8. Chang, Y. E., and L. A. Laimins. 2000. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 74:4174-4182.
9. Chang, Y. E., L. Pena, G. C. Sen, J. K. Park, and L. A. Laimins. 2002. Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J. Virol. 76:8864-8874.
10. Chiu, Y. H., J. B. Macmillan, and Z. J. Chen. 2009. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138:576-591.
11. Cogliano, V., et al. 2005. Carcinogenicity of human papillomaviruses. Lancet Oncol. 6:204.
12. DeCarlo, C. A., et al. 2010. IFN-kappa, a novel type I IFN, is undetectable in HPV-positive human cervical keratinocytes. Lab Invest. 90:1482-1491.
13. Frattini, M. G., H. B. Lim, and L. A. Laimins. 1996. In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc. Natl. Acad. Sci. U. S. A. 93:3062-3067.
14. Gewin, L., H. Myers, T. Kiyono, and D. A. Galloway. 2004. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 18:2269-2282.
15. Gilliet, M., W. Cao, and Y. J. Liu. 2008. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8:594-606.
16. Guess, J. C., and D. J. McCance. 2005. Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J. Virol. 79:14852-14862.
17. Halbert, C. L., G. W. Demers, and D. A. Galloway. 1991. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65:473-478.
18. Hasan, U. A., et al. 2007. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 178: 3186-3197.
19. Hebner, C. M., R. Wilson, J. Rader, M. Bidder, and L. A. Laimins. 2006. Human papillomaviruses target the double-stranded RNA protein kinase pathway. J. Gen. Virol. 87:3183-3193.
20. Heinz, S., et al. 2003. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J. Biol. Chem. 278:21502-21509.
21. Herdman, M. T., et al. 2006. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 27:2341-2353.
22. Huibregtse, J. M., M. Scheffner, and P. M. Howley. 1991. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10:4129-4135.
23. Kalali, B. N., et al. 2008. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIGI-mediated differential signaling. J. Immunol. 181:2694-2704.
24. Kang, D. C., et al. 2002. mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl. Acad. Sci. U. S. A. 99:637-642.
25. Karstensen, B., et al. 2006. Gene expression profiles reveal an upregulation of E2F and downregulation of interferon targets by HPV18 but no changes between keratinocytes with integrated or episomal viral genomes. Virology 353:200-209.
26. Kelley, M. L., K. E. Keiger, C. J. Lee, and J. M. Huibregtse. 2005. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J. Virol. 79:3737-3747.
27. LaFleur, D. W., et al. 2001. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J. Biol. Chem. 276:39765-39771.
28. Lai, Y., et al. 2009. Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat. Med. 15:1377-1382.
29. Leaman, D. W., et al. 2002. Identification of X-linked inhibitor of apoptosisassociated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J. Biol. Chem. 277:28504-28511.
30. Li, S., et al. 1999. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 18:5727-5737.
31. Muench, P., et al. 2009. Binding of PDZ proteins to HPV E6 proteins does neither correlate with epidemiological risk classification nor with the immortalization of foreskin keratinocytes. Virology 387:380-387.
32. Nees, M., et al. 2001. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 75:4283-4296.
33. Park, J. S., et al. 2000. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem. 275:6764-6769.
34. Perea, S. E., P. Massimi, and L. Banks. 2000. Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. Int. J. Mol. Med. 5:661-666.
35. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
36. Rathinam, V. A., and K. A. Fitzgerald. 2011. Innate immune sensing of DNA viruses. Virology 411:153-162.
37. Rincon-Orozco, B., et al. 2009. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res. 69:8718-8725.
38. Ronco, L. V., A. Y. Karpova, M. Vidal, and P. M. Howley. 1998. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12:2061-2072.
39. Rozen, S. S., and H. J. Skaletsky (ed.). 2000. Primer3 on the WWW for general users and for biologist programmers. Humana Press, Totowa, NJ.
40. Stubenrauch, F., M. Hummel, T. Iftner, and L. A. Laimins. 2000. The E8E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratinocytes. J. Virol. 74:1178-1186.
41. Terenzi, F., P. Saikia, and G. C. Sen. 2008. Interferon-inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1. EMBO J. 27:3311-3321.
42. Thomas, J. T., W. G. Hubert, M. N. Ruesch, and L. A. Laimins. 1999. Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc. Natl. Acad. Sci. U. S. A. 96:8449-8454.
43. Uze, G., and D. Monneron. 2007. IL-28 and IL-29: newcomers to the interferon family. Biochimie 89:729-734.
44. Wang, H. K., A. A. Duffy, T. R. Broker, and L. T. Chow. 2009. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev. 23:181-194.
45. Yoneyama, M., et al. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730-737.